Abstract:Acromegalic patients always demonstrate a wide range of clinic manifestations, including typical physical changes such as acral and facial features, as well as untypical neuropsychiatric and psychological disturbances. However, there is still a lack of clinical guidance on the treatment for acromegalic patients with psychiatric comorbidities. We therefore share this case to provide a reference for clinicians to manage the acromegalic patients with psychiatric symptoms. This case report describes a 41-year-old male with an 8-year history of acromegaly due to growth hormone-secreting pituitary adenoma, the maximum cross-sectional area of which was 42 mm × 37 mm demonstrated by pituitary magnetic resonance imaging (MRI). The patient received conservative medicine treatment by regularly injecting with Sandostatin LAR 10 mg per month. Two days before admission, he suddenly presented with an acute psychotic episode. In addition to the typical acromegaly-associated changes, his main clinical presentations were olfactory/auditory hallucinations, reference/persecutory delusions, instable emotion and impulsive behavior. Considering the schizophrenic-like psychoses and course features, he was diagnosed with Brief Psychotic Disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) after a multidisciplinary consultation and evaluation. He was prescribed Aripiprazole, which had less extrapyramidal symptoms and minimal influence on prolactin elevation, with the dose of 5 mg per day to control the psychiatric symptoms and he responded quite well. At the time of discharge and the follow-up 2 month later, the patient was stable without recurrence of any psychotic symptoms. The levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) 1 week after discharge were 2.22 ng/mL [normal range (0-2.47 ng/mL)] and 381 μg/L [normal range (94-284 μg/L)], respectively, which were similar to those before the psychotic episode. Results from this report further supported that small dose of Aripiprazole had little influence on hormonal levels and the development of pituitary macroadenoma. This particular case emphasizes the importance for the clinician to master and carefully identify the possible symptoms of mental disorders associated with acromegaly, and also highlights the need for further investigation in more efficient treatment strategies for acromegalic cases with psychiatric comorbidities.

Approach to the patient with controlled acromegaly and acromegalic arthropathy: clinical diagnosis and management

Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP)

Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly

Acromegaly management in the Nordic countries: A Delphi consensus survey

Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly

Acromegaly: Overview and associated temporomandibular joint disorders

Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management

Acromegaly: Incidence, patient characteristics and treatment patterns in a 10-year nationwide retrospective hospital cohort study

Current therapy and drug pipeline for the treatment of patients with acromegaly

Secondary diabetes mellitus in acromegaly: Case report and literature review

Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)

Case report: Treatment of psychiatric symptoms for an acromegalic patient with pituitary adenoma

Medical treatment of acromegaly - When the tumor size matters: A narrative review

Pseudoacromegaly—A challenging entity in the endocrine clinic: A systematic review

Acromegaly as an Expression of a Rare Disease: Description of an Unusual Clinical Case of Carney Complex

The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible

ACROMORFO study: gait analysis in a cohort of acromegalic patients

Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management

Recurrent acromegaly: a systematic review on therapeutic approaches

Response of Patients with Acromegaly to Long-acting Octreotide with regard to Regression of Pituitary Adenoma, Growth Hormone and Insulin-like Growth Factor-1